Related Experiment Video
Updated: Feb 2, 2026
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Treatment of Hypertension Induced Albuminuria
Tamara Knežević1, Lana Gellineo1, Ana Jelaković1
1Department of Nephrology, Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb, Croatia School of Medicine, University of Zagreb, Zagreb, Croatia.
Insights
Different blood pressure medications impact albuminuria differently. Early, multifactorial treatment, including ACE inhibitors/ARBs and lifestyle changes, is crucial for managing albuminuria and reducing cardiovascular and renal risk in hypertensive patients.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Albuminuria is a significant risk factor for cardiovascular and renal disease, independent of diabetes.
- Microalbuminuria is recognized as a hypertension-mediated organ damage by recent ESC/ESH guidelines.
- Albumin-to-creatinine ratio testing is recommended for hypertensive patients to assess risk.
Purpose of the Study:
- To review the differential effects of antihypertensive drug classes on albuminuria.
- To highlight the importance of an early and multifactorial approach to reduce albuminuria.
- To provide guidance on optimizing antihypertensive therapy for albuminuria management.
Main Methods:
- Review of current literature and guidelines on antihypertensive therapy and albuminuria.
- Analysis of the specific effects of different drug classes (ACEIs, ARBs, MRAs, CCBs, diuretics) on renal hemodynamics and albuminuria.
- Emphasis on combination therapy and lifestyle modifications.
Main Results:
- Antihypertensive drugs vary in their albuminuria-reducing effects, necessitating combination therapy for blood pressure and albuminuria control.
- Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are recommended in maximum doses due to their renal protective effects.
- Newer calcium channel blockers (CCBs) show promise for albuminuria reduction; diuretics are important for resistant hypertension.
Conclusions:
- An integrated approach combining pharmacotherapy (ACEIs, ARBs, potentially novel CCBs, diuretics for resistant cases) and lifestyle changes (low-salt diet) is essential for managing albuminuria.
- Early intervention, even below microalbuminuria thresholds, is advised to mitigate cardiovascular and renal risks.
- Albuminuria monitoring provides valuable prognostic information in hypertensive patients.
Abstract:
Regardless of having a similar antihypertensive effect, different antihypertensive drug classes have a different effect on albuminuria. Patients with albuminuria will usually need more than one drug to achieve blood pressure control, particularly if the aim is also to reduce albuminuria. Albuminuria is independently associated with cardiovascular and renal risk regardless of diabetes status. The recent ESC/ESH guidelines listed microalbuminuria among the hypertension-mediated organ damages. Albumin-to-creatinine ratio was suggested to be included in routine workup for evaluation of every hypertensive patient and changes in albuminuria were considered to have moderate prognostic value. Because of its specific effects on renal hemodynamic and glomerular structure, the ACEIs and ARBs should be prescribed in maximum tolerated doses. The MRAs can be considered in uncontrolled hypertensive patients. The CCBs can be used in addition to the RAAS blockade. Data on antialbuminuric effect of the new CCBs generation (T-type and N-type calcium channel blockers) is promising and they might be preferential CCBs when available. In case of resistant hypertension, thiazide or thiazide-like diuretic has to be added into the combination with RAAS blockers and other antihypertensive drugs. Low-salt intake has to be recommended for all hypertensive patients, particularly those with albuminuria. A multifactorial and early antialbuminuric approach should be started even when albuminuria values are below the cut-off value for microalbuminuria.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:28Hypertension I: Introduction